Navigation Links
All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
Date:5/26/2011

enotype 1 subjects;
  • PSI-7977 400mg QD and BMS-790052 60mg QD for 24 weeks in genotype 2 or 3 subjects;
  • PSI-7977 400mg QD, BMS-790052 60mg QD and ribavirin for 24 weeks in genotype 1 subjects;
  • PSI-7977 400mg QD, BMS-790052 60mg QD and ribavirin for 24 weeks in genotype 2 or 3 subjects.

  • Additional details can be found at www.clinicaltrials.gov.

    About Pharmasset

    Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in three Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, recently reported safety and efficacy data from 14-days of monotherapy as well as 14 days in combination with the pyrimidine, PSI-7977. An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin third quarter 2011. Mericitabine (RG7128) continues in two Phase 2b trials and one interferon-free trial conducted through a strategic collaboration with Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    Office: +1 (609) 865-0693

    Forward-Looking Statements

    Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform
    '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
    2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
    3. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
    4. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
    5. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
    6. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
    7. Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
    8. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
    9. New Interim Data About Combination Oral Contraceptives
    10. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
    11. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... IRVINE, Calif. , Aug. 31, 2015 /PRNewswire/ ... business and government, where regulations are often strict ... environment is driving a demand for professionals who ... interpret these regulations across a product lifecycle and ... organization. The University of California, Irvine Extension ...
    (Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
    (Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
    Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
    ... 2011 Reportlinker.com announces that a new market research ... Global Injectable Drug Delivery Market (2010 - 2015) ... KEY TAKE AWAYS * To ... its various sub-segments with respect to types of systems, ...
    ... Reportlinker.com announces that a new market research report ... European Markets for Minimally Invasive Spinal Devices ... The European minimally invasive spinal implant ... Rapid growth of the MIS interbody and MIS ...
    Cached Medicine Technology:Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 2Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 3Reportlinker Adds European Markets for Minimally Invasive Spinal Devices 2011 2
    (Date:9/1/2015)... ... September 01, 2015 , ... Situations requiring fast, easy-to-understand business ... most convenient time for everyone involved. These occasions highlight the value of a ... Services has real people available to handle any translation assignment at any ...
    (Date:9/1/2015)... (PRWEB) , ... September 01, ... ... announced today it has established the MAP Recovery Network, the Premier Outcomes-Driven ... treatment providers. This rapidly-growing alliance is dedicated to the provision of quality ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... area to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides ... veins in the hands, delivering smooth, natural-looking results that can last up to one ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... sponsored an educational workshop for physician assistants (PAs) practicing in orthopedics. The workshop, ... Zeel™” was held by Dr. Erick Salado, an orthopedic surgeon at South Florida ...
    (Date:9/1/2015)... ... 01, 2015 , ... Curly Hair Solutions™ is thrilled to ... anticipated partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution ... the Curly Hair Solutions™ team could not be more delighted to see their ...
    Breaking Medicine News(10 mins):Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2
    ... , , WEDNESDAY, Nov. 14 (HealthDay News) -- During a ... drugs to be sold by pharmacists without a prescription, ... for and against the proposal by representatives of various ... day,s end, the FDA officials said they weren,t ready ...
    ... a,statement from Jeff Levi, Executive Director of Trust ... (TFAH) urges Congress to override the,President,s veto of ... Agencies Appropriations bill., The Labor/HHS bill provides ... states, territories, localities and hospitals to prepare for,public ...
    ... Kalamazoo, Mich.-based,Stryker Corporation and its former outpatient ... pay the United States $16.6,million to settle ... and other federal health care programs, the ... allegations that Physiotherapy, which is based,in Memphis, ...
    ... announced today,that the U.S. Food and Drug ... beta) for the treatment of anemia,associated with ... patients,on dialysis and patients not on dialysis. ... (CKD). MIRCERA is the only FDA-approved,erythropoiesis-stimulating agent ...
    ... Conference Call Scheduled for November 20, NAPA, Calif., ... specialty life sciences company engaged in the,study of senescense, ... skincare,and dermatological therapeutics today announced financial results for the,quarter ... quarter 2007 were $469,000 compared to,$2,027,000 for the same ...
    ... Natural Nutrition,(OTC Bulletin Board: NNTN) ( http://www.naturalnutritioninc.com ) ... of 10-QSB. Chris Mathers, CFO of,Natural Nutrition said, ... filing for Natural Nutrition will not be filed ... record revenue of $12.644,million and record EBITDA of ...
    Cached Medicine News:Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Stryker Corp. & Physiotherapy Associates to Pay U.S. $16.6 Million for Alleged False Claims to Federal Health Care Programs 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 3Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 2Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 3Health News:Natural Nutrition to Report Record Revenue and EBITDA in Late Filing of 10-QSB 2
    ... to 350 Liters of pure water, Complete, ... of Purified Water,Millipores compact S.D.S. Storage and ... to 350 liters of purified water produced ... maintain consistent purity of stored water, provide ...
    ... to 350 Liters of pure water, Complete, ... of Purified Water,Millipores compact S.D.S. Storage and ... to 350 liters of purified water produced ... maintain consistent purity of stored water, provide ...
    ... 350 Liters of pure water, Complete, Compact ... Purified Water,Millipores compact S.D.S. Storage and Distribution ... 350 liters of purified water produced by ... consistent purity of stored water, provide effective ...
    ... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
    Medicine Products: